Active Ingredient
(in each extended-release tablet)
Guaifenesin USP 600 mg
The following Structured Product Label (SPL) was submitted to the FDA by Bluepoint Laboratories for the product Guaifenesin (NDC 68001-561). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient, purpose, uses, warnings, ask a doctor before use if you have, stop use and ask a doctor if, if pregnant or breast-feeding,, keep out of reach of children, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
(in each extended-release tablet)
Guaifenesin USP 600 mg
Expectorant
Do not use
ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).
colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, povidone, and pregelatinised starch (maize)
1-855-274-4122 (Monday – Friday 8:30 AM to 5:00 PM EST) You may also report side effects to this phone number.
Manufactured by:
APL Healthcare Limited Unit-IV.
Tirupati (Dt) - 524421, India
For BluePoint Laboratories
Made in India
Code: AP/DRUGS/04/2016
Rev: 10/2022
Blister Pack : NDC 68001-561-16
Carton Pack : NDC 68001-561-17
Guaifenesin Extended-Release Tablets 600 mg
EXPECTORANT
12 HOUR
80 Extended-Release Tablets
* Please review the disclaimer below.